Impact of SARS‐CoV‐2 Infection (COVID‐19) on Cytochromes P450 Activity Assessed by the Geneva Cocktail-Reference-Cited by-同舟云学术

Impact of SARS‐CoV‐2 Infection (COVID‐19) on Cytochromes P450 Activity Assessed by the Geneva Cocktail

Published:2021-09-21 Issue:5 Volume:110 Page:1358-1367
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin Pharmacol Ther

Author:

Lenoir Camille¹²,Terrier Jean¹³,Gloor Yvonne¹,Curtin François¹⁴,Rollason Victoria¹⁵,Desmeules Jules Alexandre¹²⁵,Daali Youssef¹²⁵,Reny Jean‐Luc³⁵,Samer Caroline Flora¹⁵

Affiliation:

1. Division of Clinical Pharmacology and Toxicology Department of Anaesthesiology, Pharmacology, Intensive Care and Emergency Medicine Geneva University Hospitals Geneva Switzerland

2. Institute of Pharmaceutical Sciences of Western Switzerland University of Geneva Geneva Switzerland

3. Division of General Internal Medicine Department of Medicine Geneva University Hospitals Geneva Switzerland

4. Personalized Health and Related Technologies Swiss Federal Institute of Technology in Zurich Zurich Switzerland

5. Faculty of Medicine University of Geneva Geneva Switzerland

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.2412

Reference55 articles.

1. A Novel Coronavirus from Patients with Pneumonia in China, 2019

2. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients

3. The role of biomarkers in diagnosis of COVID-19 – A systematic review

4. Cytokine Storm

5. Characterization of the Inflammatory Response to Severe COVID-19 Illness

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comment on: Increased Theophylline Plasma Concentrations in a Patient With COVID-19;Annals of Pharmacotherapy;2024-09-09

2. Liver Fibrosis Stages Affect Organic Cation Transporter 1/2 Activities in Hepatitis C Virus-Infected Patients;Pharmaceuticals;2024-07-01

3. Impact of obesity and roux‐en‐Y gastric bypass on the pharmacokinetics of (R)‐ and (S)‐omeprazole and intragastric pH;CPT: Pharmacometrics & Systems Pharmacology;2024-06-24

4. Therapeutic Drug Monitoring of Olanzapine: Effects of Clinical Factors on Plasma Concentrations in Psychiatric Patients;Therapeutic Drug Monitoring;2024-06-03

5. Circulating Biomarkers Instead of Genotyping to Establish Metabolizer Phenotypes;Annual Review of Pharmacology and Toxicology;2024-01-23